Artiva Biotherapeutics Inc. (ARTV)

$11.77 -0.23 (-1.92%)
Market Cap N/A
Revenue (ttm) 33.49M
Net Income (ttm) -27.70M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 342,500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associa...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 267 4467
Address:
5505 Morehouse Drive, Suite 100, San Diego, United States
RetentionRune
RetentionRune Dec. 27 at 2:34 PM
$ARTV Positioning reflects caution while awaiting confirmable progress; capital allocation choices will face heightened scrutiny — execution across cycles would support multiple expansion. Patience helps only if fundamentals keep strengthening.
0 · Reply
DowntimeD
DowntimeD Dec. 25 at 12:57 PM
$ARTV The opportunity set remains meaningful, but only if discipline keeps pace with ambition. The company must show that scale translates into durable margins rather than fragility. Strategic clarity can reduce risk premiums even before growth accelerates. Sustainable upside exists, but only alongside disciplined follow‑through.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 25 at 12:33 AM
$ARTV
0 · Reply
amda
amda Dec. 23 at 6:30 PM
$ARTV a little overdone here? new position at $4.15 just now....
0 · Reply
Think_Bigly
Think_Bigly Dec. 20 at 6:47 PM
$ARTV the analysts didn't show us this:. - Affimed innate cell engager (ICE®) + Artiva in HDL combination. 'RMAT designation is intended to expedite the development and review of regenerative medicine therapies, including cell therapies, that aim to address serious or life-threatening conditions. RMAT designation provides the same expedited review benefits as a Breakthrough Therapy Designation, but is exclusively focused on regenerative medicine products.' https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
CaptChaos145
CaptChaos145 Dec. 19 at 3:51 PM
$ARTV Thus should get to $6 by early next week. Technicals are lined up.
0 · Reply
swinda42
swinda42 Dec. 19 at 3:13 PM
$ARTV
0 · Reply
Think_Bigly
Think_Bigly Dec. 18 at 6:25 PM
$ARTV for the next week, tax loss selling.
0 · Reply
Zackpedia
Zackpedia Dec. 17 at 10:55 PM
$ARTV You could’ve sold when I alerted and bought back at 4.2 if you wanted, hit Follow and subscribe to get my alerts on time and make money
1 · Reply
p983
p983 Dec. 17 at 3:05 PM
$ARTV Inside 4.17
0 · Reply
Latest News on ARTV
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Nov 12, 2025, 7:20 AM EST - 7 weeks ago

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:00 AM EST - 7 weeks ago

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Nov 3, 2025, 4:05 PM EST - 2 months ago

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

Oct 30, 2025, 4:17 PM EDT - 2 months ago

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Oct 16, 2025, 4:05 PM EDT - 2 months ago

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Aug 25, 2025, 4:05 PM EDT - 4 months ago

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 4:05 PM EDT - 7 months ago

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

May 13, 2025, 4:05 PM EDT - 8 months ago

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 8 months ago

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Apr 28, 2025, 4:35 PM EDT - 8 months ago

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Apr 8, 2025, 4:05 PM EDT - 9 months ago

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 4:05 PM EDT - 9 months ago

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 4:05 PM EDT - 10 months ago

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 4:05 PM EST - 11 months ago

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Jan 29, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Nov 11, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Aug 13, 2024, 2:14 PM EDT - 1 year ago

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Jul 22, 2024, 3:55 PM EDT - 1 year ago

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

Jul 20, 2024, 4:50 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

ACTU ARDT CON LINE OS QMMM TWFG

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

Jul 18, 2024, 7:08 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

RetentionRune
RetentionRune Dec. 27 at 2:34 PM
$ARTV Positioning reflects caution while awaiting confirmable progress; capital allocation choices will face heightened scrutiny — execution across cycles would support multiple expansion. Patience helps only if fundamentals keep strengthening.
0 · Reply
DowntimeD
DowntimeD Dec. 25 at 12:57 PM
$ARTV The opportunity set remains meaningful, but only if discipline keeps pace with ambition. The company must show that scale translates into durable margins rather than fragility. Strategic clarity can reduce risk premiums even before growth accelerates. Sustainable upside exists, but only alongside disciplined follow‑through.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 25 at 12:33 AM
$ARTV
0 · Reply
amda
amda Dec. 23 at 6:30 PM
$ARTV a little overdone here? new position at $4.15 just now....
0 · Reply
Think_Bigly
Think_Bigly Dec. 20 at 6:47 PM
$ARTV the analysts didn't show us this:. - Affimed innate cell engager (ICE®) + Artiva in HDL combination. 'RMAT designation is intended to expedite the development and review of regenerative medicine therapies, including cell therapies, that aim to address serious or life-threatening conditions. RMAT designation provides the same expedited review benefits as a Breakthrough Therapy Designation, but is exclusively focused on regenerative medicine products.' https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
CaptChaos145
CaptChaos145 Dec. 19 at 3:51 PM
$ARTV Thus should get to $6 by early next week. Technicals are lined up.
0 · Reply
swinda42
swinda42 Dec. 19 at 3:13 PM
$ARTV
0 · Reply
Think_Bigly
Think_Bigly Dec. 18 at 6:25 PM
$ARTV for the next week, tax loss selling.
0 · Reply
Zackpedia
Zackpedia Dec. 17 at 10:55 PM
$ARTV You could’ve sold when I alerted and bought back at 4.2 if you wanted, hit Follow and subscribe to get my alerts on time and make money
1 · Reply
p983
p983 Dec. 17 at 3:05 PM
$ARTV Inside 4.17
0 · Reply
SWEEN24
SWEEN24 Dec. 16 at 10:29 PM
$ARTV oh no. Now im blocked from reading nonsensical babble by love to learn. How will i ever move on.
0 · Reply
GSP
GSP Dec. 16 at 10:19 PM
$ARTV $VOR $NXDR $QCLS $CLYM
0 · Reply
lenten
lenten Dec. 16 at 9:51 PM
$ARTV $VOR $NXDR $QCLS $CLYM
0 · Reply
SWEEN24
SWEEN24 Dec. 16 at 9:23 PM
$ARTV how this guy has 1k followers, ill never know. Never understand anything he posts.
2 · Reply
Love_To_Learn
Love_To_Learn Dec. 16 at 7:37 PM
$ARTV me off 4.47*
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 16 at 7:37 PM
$ARTV acquired 8.7 million shares off the books now
0 · Reply
Onebasecapital
Onebasecapital Dec. 16 at 6:30 PM
$ARTV down -30% on less than 3 million shares after near +100% run up yesterday on +40 million shares. I'd be 'fearful' if price was down -30% on 10mil shrs or more. 'Healthy' pullback today.
1 · Reply
elmono
elmono Dec. 16 at 6:01 PM
$ARTV sub 4 and we see accelerated selling. Most buying done between 4-5….so baggies are being created as we speak. Probably dump below 3
0 · Reply
Zackpedia
Zackpedia Dec. 16 at 5:05 PM
$ARTV Down to 4.6 now
2 · Reply
u_R_a_bagholder
u_R_a_bagholder Dec. 16 at 4:46 PM
$ARTV who got bagged up in the blatant pump n dump yesterday ?
0 · Reply
IBOTTheDipAndTheDipWon
IBOTTheDipAndTheDipWon Dec. 16 at 4:30 PM
$ARTV Now that I'm no longer short the expected dump comes.
0 · Reply
doomerboomer
doomerboomer Dec. 16 at 4:02 PM
$ARTV Next time dumb analysts say something, fart in their face and take a dump 🤣. If all the analysts projections were mostly right, we would all be billionaires 😂😂. Shitstoks are shit for a reason.
1 · Reply